Tesla's stock (TSLA) experienced a significant decline last week, wiping out $152 billion in market value, following a public dispute between Elon Musk and Donald Trump. Morgan Stanley analyst Adam Jonas, while acknowledging potential near-term volatility and alienation of buyers, maintains an Overweight rating and a $410 price target, citing Tesla's leadership in AI, autonomy, and manufacturing as enduring strengths; however, the broader analyst consensus remains a Hold rating with an average price target suggesting range-bound movement.
Tesla's stock experienced a significant $152 billion decline in market value following a public social media dispute between CEO Elon Musk and former President Donald Trump. This event, characterized by Trump's threat to withdraw federal subsidies and contracts and Musk's counter-jabs, has amplified investor concerns, reflected in a negative sentiment score of -0.3 for TSLA and a generally uncertain market tone. Morgan Stanley analyst Adam Jonas, while maintaining an Overweight rating and a $410 price target (implying a 36% one-year gain), acknowledges the potential for the spat to temporarily alienate buyers across the political spectrum and anticipates near-term volatility. Jonas downplays the materiality of the phase-out of EV tax credits from the 'Big Beautiful Bill' to Tesla's long-term outlook, emphasizing instead the company's enduring strengths in AI leadership, autonomy, manufacturing, supply chain re-architecture, and renewable power, which he views as largely apolitical. However, this bullish stance contrasts with the broader Wall Street consensus, which rates Tesla a Hold, based on 16 Buys, 10 Holds, and 10 Sells, with an average price target of $285.91, suggesting shares are expected to remain range-bound. The market impact score of 0.65 underscores the sensitivity of Tesla's valuation to such non-operational events.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Overall Sentiment
mixed
Sentiment Score
-0.05
Ticker Sentiment